Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Long-Term Deferred Tax (2018 - 2026)

Anika Therapeutics has reported Long-Term Deferred Tax over the past 10 years, most recently at $1.2 million for Q1 2026.

  • Quarterly Long-Term Deferred Tax fell 3.2% to $1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Mar 2026, down 3.2% year-over-year, with the annual reading at $1.3 million for FY2025, 8.33% up from the prior year.
  • Long-Term Deferred Tax was $1.2 million for Q1 2026 at Anika Therapeutics, down from $1.3 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $1.5 million in Q1 2023 and troughed at $1.2 million in Q1 2026.
  • The 5-year median for Long-Term Deferred Tax is $1.3 million (2024), against an average of $1.3 million.
  • Year-over-year, Long-Term Deferred Tax fell 20.95% in 2024 and then rose 8.33% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $1.4 million in 2022, then increased by 2.76% to $1.5 million in 2023, then fell by 20.95% to $1.2 million in 2024, then increased by 8.33% to $1.3 million in 2025, then decreased by 9.8% to $1.2 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Long-Term Deferred Tax are $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025).